A cost-effectiveness analysis of the Chronic Disease Management Program in patients with hypertension in Korea

Abstract Background The Chronic Disease Management Program (CDMP) of Korea has been introduced to improve care continuity in patients with hypertension and diabetes. Objective This study evaluated the cost effectiveness CDMP from perspective healthcare payer. Methods A cost-effectiveness analysis was performed based on a Markov simulation model. effect versus usual compared individuals aged 40 years or above. two strategies were presumed result difference incidence myocardial infarction, stroke, chronic kidney disease. model analyzed over lifetime cohort. Incremental ratio (ICER) calculated by dividing costs effects (quality adjusted life years, QALYs) between strategies. Costs expressed Korean Won (KRW). Results ICER value participation strategy −5 761 088 KRW/QALY care. Similar tendencies found when limiting population only clinic users (−3 843 355 KRW/QALY) national health examination participants (−5 595 185 KRW/QALY). Conclusion highly cost-effective Implementing efficient policies that enhance coordination outcomes is important.